𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma

✍ Scribed by Toni K. Choueiri; Robert Dreicer; Brian I. Rini; Paul Elson; Jorge A. Garcia; Snehal G. Thakkar; Rachid C. Baz; Tarek M. Mekhail; Holly A. Jinks; Ronald M. Bukowski

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
438 KB
Volume
107
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A Phase II study of irinotecan in patien
A Phase II study of irinotecan in patients with advanced renal cell carcinoma
✍ Karim Fizazi; FrΓ©dΓ©ric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 3 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p

A pilot study of thalidomide in patients
A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma
✍ Danai D. Daliani; Christos N. Papandreou; Peter F. Thall; Xuemei Wang; Cherie Pe πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 96 KB πŸ‘ 2 views

## Background: The highly vascular nature of renal cell carcinoma (rcc) suggests that angiogenesis inhibition may be therapeutic for patients with this disease. thalidomide inhibits basic fibroblast growth factor and vascular endothelial growth factor (vegf)-induced angiogenesis. ## Methods: In a

Phase 2 trial of talactoferrin in previo
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
✍ Eric Jonasch; Walter M. Stadler; Ronald M. Bukowski; Teresa G. Hayes; Atul Varad πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 84 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Talactoferrin (TLF), a recombinant form of human lactoferrin (hLF), is an immunomodulatory iron‐binding glycoprotein first identified in breast milk. Its immunomodulatory functions include activation of natural killer (NK) and lymphokine‐activated killer cells and enhanc